Radiotherapy alone is often used to treat early-stage glottic cancer (ESGC), a cancer of the vocal chords, however, the optimal radiation treatment schedule remains unknown, until now.
Patients who expressed the tumor antigen NY-ESO-1 had more aggressive cancers and were more likely to die early from their disease, according to a large study conducted by Roswell Park Cancer Institute researchers and published online ahead of print in the journal Gynecologic Oncology.
The University of Texas MD Anderson Children’s Cancer Hospital joins Houston restaurants and businesses to host its second annual Prom Party Palooza, a prom for teen cancer patients and their families. The glamorous night takes place at MD Anderson on Saturday, April 29 from 6 to 9 p.m.
A biopolymer structure enriched with nutrients shows how immunotherapy could be adapted for solid tumors, according to study in The Journal of Clinical Investigation.
Second cancers in children and adolescents and young adults (AYA) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients ages 15-39 overall, a new study by UC Davis researchers has found."Second Primary Malignant Neoplasms and Survival in Adolescent and Adult Cancer Survivors" is published today in JAMA Oncology.
An early round of clinical testing shows that users of Opdivo, a drug sanctioned for treatment of small-cell lung cancer, more than tripled their five-year survival rate beyond the statistical average.
After studying viruses for 15 years, Dr. Anthony van den Pol believes he has found one that can safely and effectively kill chemotherapy-resistant ovarian cancer.
The NCCN Radiation Therapy Compendium™, launched in March 2017, provides a single access point for radiation therapy recommendations within 33 NCCN Guidelines®.
Select breast cancer patients who achieved pathologic complete response (pCR) after chemotherapy may be able to avoid follow-up breast and lymph node, or axillary, surgery, according to new findings from researchers at The University of Texas MD Anderson Cancer Center. The study, published today in JAMA Surgery, identifies the exceptional responders who are at lowest risk for local metastases and thereby are candidates for less invasive treatment options.
Small trial uses chloroquine to nix the process of "autophagy" that some cancer cells use to resist treatment, resensitzing glioblastoma to targeted therapy
Oncology community professionals are concerned about the ability of their patients to access cancer screening and treatment under the proposed American Health Care Act, according to a survey conducted March 23–25, 2017 at the National Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ at the Rosen Shingle Creek in Orlando, Florida.
The University of Texas MD Anderson Cancer Center and Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced a multi-year strategic alliance agreement involving multi-arm clinical trials to evaluate the safety and efficacy of TIL therapy in ovarian, various sarcomas, and pancreatic cancers.
Karen Burns White, Deputy Associate Director of Dana-Farber/Harvard Cancer Center’s (DF/HCC) Initiative to Eliminate Cancer Disparities (IECD) since 2001, has been honored by the Massachusetts Medical Society as the 2017 recipient of the society’s Reducing Health Disparities Award. The honor recognizes an individual who has made outstanding contributions to reducing health disparities due to race, socioeconomic status, age, education, or sexual orientation.
The Global Health Catalyst Cancer Summit is an annual event that provides a forum for global health stakeholders to network, share knowledge and strengthen high-impact international collaborations that save lives while reducing global health disparities. Participants at the GHC Summit come from all across North America, Europe, Africa, and other impacted nations. Participants include leaders from the World Health Organization, World Bank Group, policy makers, Diaspora organizations, community leaders, U.S. congressional representatives, internationally recognized physicians and researchers, industry, professional sports celebrities and other cancer advocates.
For the fifth time in five years, Dana-Farber Cancer Institute has been recognized as a leader in LGBTQ Healthcare Equity by the Human Rights Campaign (HRC) Foundation. The distinction is achieved through evaluation by the Healthcare Equality Index (HEI), an annual survey that measures inclusive policies and practices related to LGBT patients, visitors, and staff at nearly 600 medical facilities nationwide.
During this National Minority Health Month, there is a focus on bridging health equity in our communities including ensuring minority populations have access to high quality cancer screenings and treatments, adequate insurance coverage and other services. Health disparities researcher Jennifer Tsui, PhD of Rutgers Cancer Institute of New Jersey shares some insight.
Luis A. Diaz, MD, has been named the Head of the Division of Solid Tumor Oncology in the Department of Medicine at Memorial Sloan Kettering (MSK). An accomplished physician, pioneering researcher, and leader in the field of clinical oncology, Dr. Diaz most recently served as an associate professor of oncology at the Johns Hopkins University School of Medicine.
The third annual “Splash Away Cancer!” fundraising event takes place May 20, 2017. All proceeds support patient care and cancer research programs at The University of New Mexico Comprehensive Cancer Center.
An international team of collaborators retroactively examined the associations between survival among patients diagnosed with invasive epithelial ovarian cancer and those patients’ history of hypertension, heart disease, diabetes, and medications taken for those conditions. They found that while hypertension was linked to better outcomes, diabetes was associated with decreased survival.
University of Colorado Cancer Center Study uncovers discrepant decision-making for use of 21-gene assay in women with cancer:
• Testing occurs in high-risk population, despite current evidence
• Non-concordance with NCCN Guidelines® recommendations
• Racial and socio-economic disparities found in testing use
An international effort to analyze the entire database of Ebola virus genomes from the 2013-2016 West African epidemic reveals insights into factors that sped or slowed the rampage and calls for using real-time sequencing and data-sharing to contain future viral disease outbreaks.
Celebrating all types of libraries during National Library Week (April 9 - 16), Rutgers Cancer Institute of New Jersey is recognizing its own patient resources at its specialized library.
A biochemical analysis study has discovered a new role for the DNA2 enzyme.
The research, which was completed in the lab of Patrick Sung, professor of molecular biophysics and biochemistry at the Yale School of Medicine, looked at the way in which DNA2 repairs breaks in DNA that lead to the abnormalities that cause cancer.
The Lobos vs. Cancer Gala event, which celebrates its tenth year on Saturday, May 20, raises money for cancer research and treatment at UNM Cancer Center.
After 4-week trial of added rice bran, navy bean powder or neither, both the rice bran and navy bean groups showed increased dietary fiber, iron, zinc, thiamin, niacin, vitamin B6, folate, and alpha-tocopherol. The rice bran group also showed increased microbiome richness and diversity. When researchers treated colorectal cancer cells with stool extracts from these groups, they saw reduced cell growth from the groups that had increased rice bran and navy bean consumption.
Dr. Kristin Anderson from Fred Hutch will describe preclinical research on T-cell therapy showing how engineered T cells are able to kill both human and mouse ovarian cancer cells in the lab and significantly extend survival in a mouse model.
Oncora Medical, a precision radiation oncology software company, and The University of Texas MD Anderson Cancer Center, today announced a strategic alliance focusing on building the next generation of precision medicine software for radiation oncology.
Dana-Farber Cancer Institute scientists report a number of patients in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene.
New Dana-Farber study shows patients with platinum resistant ovarian cancer who wouldn’t be expected to respond to a PARP inhibitor had partial shrinkage of their tumor with the addition of a kinase inhibitor.
Dr. Marie Bleakley, a pediatric oncology physician-scientist at Fred Hutchinson Cancer Research Center, has received a 2017 Innovative Research Grant in immuno-oncology from Stand Up To Cancer.
New research suggests that some patients with head and neck cancers can benefit by continuing treatment with an immunotherapy drug after their tumors show signs of enlargement according to investigators at Dana-Farber Cancer Institute and other organizations.
What if your body’s ancient defenses against invading bacteria could be hijacked to help kill cancer? In a small sarcoma trial, Fred Hutch scientists led by Dr. Seth Pollack see signs of immune attack after injections of a bacteria-inspired drug.
An Innovative Research Grant from Stand Up to Cancer will help a University of Texas MD Anderson Cancer Center physician scientist and her team understand how the bacteria in the digestive tracts of melanoma patients affects their response to a common immunotherapy drug.
NCCN Imaging AUC™ provide a single access point for all oncology imaging recommendations within the NCCN Guidelines®; currently, NCCN Imaging AUC™ are available for 48 NCCN Guidelines.
Research has shown that by themselves, the diabetes drug metformin and cholesterol-lowering drugs known as statins are associated with reduced cancer mortality, but little is known about the effect on pancreatic cancer mortality when these drugs are taken together. Investigators at Rutgers Cancer Institute of New Jersey examined SEER Medicare data to further explore this approach and found that exposure to statins for these patients was significantly associated with reduced overall mortality.
Research findings from Memorial Sloan Kettering Cancer Center (MSK) will be featured in this year’s American Association for Cancer Research (AACR) Annual Meeting press program. The AACR is the oldest and largest professional organization dedicated to advancing cancer research, and the press program highlights cancer research that a panel of AACR experts considers the most significant of the year and deserving of media attention.
Dr. Amanda Paulovich, whose lab has a leading role in the Beau Biden Cancer Moonshot, will speak April 5 at the AACR annual meeting about her lab’s pioneering methods to measure proteins that serve as tumor markers.
A Yale Cancer Center team analyzed HNSCC data from The Cancer Genome Atlas to identify molecular characteristics of HPV+ HNSCC and correlated them with patient outcomes.
Workers exposed to chemicals like deodorizers, sanitizers, disinfectants and sterilizers on the job may be more likely than other people to develop thyroid cancer, a recent study suggests.
A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (ADT) – a testosterone-lowering therapy and a common treatment for the disease – and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.
The Kevin Rudi Foundation will host its third annual Superhero 5K Fun Run to raise money for sarcoma research at The University of New Mexico Comprehensive Cancer Center.
Ludwig Cancer Research released today the full scope of advances to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Washington D.C., April 1-5, 2017.
Scientists from the Fred Hutchinson Cancer Research Center in Seattle are scheduled to present and discuss the latest developments in immunotherapy and proteomics at the American Association for Cancer Research Annual Meeting, Research Propelling Cancer Prevention and Cures, on April 1-5. What follows is a selection of the more than 30 Hutch presentations at the AACR gathering